Searchable abstracts of presentations at key conferences in endocrinology

ea0002oc23 | Growth Regulation | SFE2001

Pituitary Tumour Shrinkage During Treatment of Acromegaly with Sandostatin LAR

Jenkins P , Yeo P , Besser G , Evanson J , Monson J

Transsphenoidal surgery results in biochemical cure of approximately 50% of all acromegalic patients, depending on tumour size and surgical expertise. It is uncertain whether prior treatment with somatostatin analogues would result in tumour shrinkage and therefore improve the efficacy of subsequent surgery. Aims: To determine whether 6 months de novo treatment with Sandostatin LAR results in tumour shrinkage. Methods: 6 patients (mean age 53 yr; range 42-...

ea0002p92 | Steroids | SFE2001

MODULATION OF CORTISOL METABOLISM DURING TREATMENT OF ACROMEGALY IS INDEPENDENT OF BODY COMPOSITION AND INSULIN SENSITIVITY

Monson J , Jenkins P , Taylor N , Yeo P , Carroll P , Camacho-Hubner C , Noonan K , Perry L , Besser G

Cortisol metabolism is modulated by inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta HSD1) during GH replacement (Weaver et al, Clin Endocrinol, 1994, 41, 639; Gelding et al, Clin Endocrinol, 1998, 48, 153) and in active acromegaly (Moore et al, J Clin Endocrinol Metab, 1999, 84, 4172). 11 beta HSD1 activity is also influenced by both fat mass and insulin. To determine the relative contribution of GH/IGF-I to alteration in cortisol metabolism we have examined...